Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7425913
Reference Type
Journal Article
Title
Roles and mechanisms of alternative splicing in cancer - implications for care
Author(s)
Bonnal, SC; López-Oreja, I; Valcárcel, J; ,
Year
2020
Is Peer Reviewed?
1
Journal
Nature Reviews. Clinical Oncology
ISSN:
1759-4774
EISSN:
1759-4782
Publisher
NATURE RESEARCH
Location
BERLIN
Page Numbers
457-474
Language
English
PMID
32303702
DOI
10.1038/s41571-020-0350-x
Web of Science Id
WOS:000550779400009
URL
http://www.nature.com/articles/s41571-020-0350-x
Exit
Abstract
Removal of introns from messenger RNA precursors (pre-mRNA splicing) is an essential step for the expression of most eukaryotic genes. Alternative splicing enables the regulated generation of multiple mRNA and protein products from a single gene. Cancer cells have general as well as cancer type-specific and subtype-specific alterations in the splicing process that can have prognostic value and contribute to every hallmark of cancer progression, including cancer immune responses. These splicing alterations are often linked to the occurrence of cancer driver mutations in genes encoding either core components or regulators of the splicing machinery. Of therapeutic relevance, the transcriptomic landscape of cancer cells makes them particularly vulnerable to pharmacological inhibition of splicing. Small-molecule splicing modulators are currently in clinical trials and, in addition to splice site-switching antisense oligonucleotides, offer the promise of novel and personalized approaches to cancer treatment.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity